FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers have discovered that an FDA-approved drug, AMD3100, can help immunotherapy treat a rare liver cancer called fibrolamellar carcinoma. The drug works by preventing tumors from trapping immune T cells, allowing them to attack the cancer.
Why it matters
This finding offers a potential new treatment pathway for a rare, aggressive cancer that currently lacks effective therapeutic options.
A rare and aggressive form of liver cancer has long resisted immunotherapy, a treatment that helps the body's own immune system attack cancer cells. Now, researchers have identified a potential way to overcome that resistance using an FDA-approved drug that is already available for another medical condition.
The article summarizes scientific research findings without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in